ClinicalTrials.gg
Active, not recruitingNCT06901674Updated Mar 6, 2026

Stimulating the Cochlear Apex Without Longer Electrodes

An interventional study of Modified surgical approach and Cochlear Nucleus CI632 cochlear implant in Deafness With a Cochlear Implant, sponsored by NYU Langone Health. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Aug 2022, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Deafness with a site in United States — 19 open to participants now, 22 under way, 1 of them phase 3. Deafness · United States.

Enrollment
23rd of 44
40 · median 41
Started
2022
with 4 others
No phase
31 of 63
10 open now
Primary completion
2027-01
later than 7 of 21 live
Registered
60th of 63
by date
Lead sponsor
5 of 63
NYU Langone Health

Among the 63 studies in Deafness with a site in United States, this one is the 23rd largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2022, is one of 31 with no phase, reaches primary completion later than 7 of the 21 other live ones, and was the 60th registered.

Deafness

161 studies on the registry are indexed under Deafness; 46 are open to participants now.

Browse Deafness studies →

Open to participants now

19 of the 63 studies in Deafness with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Deafness studies recruiting now, 11 (37%) set no upper age limit and 10 (33%) stop at 75 or younger; 19 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Deafness with a site in United States, or all of them as a file.
02

Study summary

The most common cochlear implant intervention provides an electrode array that stimulates less than half of the length of the cochlea, leaving the regions which represent lower frequencies in the normally functioning ear unstimulated. Providing stimulation over the entire cochlea has the potential to improve speech understanding, sound quality, as well as spectral and temporal representation. Increasing the length of the electrode array to cover a greater portion of the cochlea has many potential issues, including increased damage to the cochlea and probability of incomplete insertions. In this study, a new technique is being investigated that allows stimulation across the entire cochlear extent without increasing the length of the electrode array. The purpose of this study is to evaluate the benefit of the new technique on speech understanding outcomes. Additionally, the study will investigate the new configuration to explore how the auditory system encodes temporal and spectral information.

03

Conditions studied

  • Deafness With a Cochlear Implant

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants in this study must have already been evaluated at the NYU cochlear implant center as being eligible for a cochlear implant.
  • They must have decided to receive a cochlear implant manufactured by Cochlear Limited and have been diagnosed with a moderate to profound sensorineural hearing loss in the ear to be implanted.
  • Individuals who have already been implanted with a cochlear implant manufactured by Cochlear Limited with or without this new approach may also participate in this study.

Exclusion criteria

Exclusion Criteria:

  • They are under the age of 18
  • They have not been diagnosed with a moderate to profound sensorineural hearing loss in the ear to be implanted
  • Have >15 years of profound deafness
  • Have not chosen to receive a cochlear implant manufactured by Cochlear Limited
  • Are pregnant or plan to conceive within 6 months of consenting
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Apical ground electrode

    Participants in this group will have already received a cochlear implant using the new approach or be receiving a cochlear implant with the new approach.

    Procedure: Modified surgical approach · Device: Cochlear Nucleus CI632 cochlear implant

  • Active comparator
    Standard location ground electrode

    Participants in this group have received a cochlear implant with the typical ground electrode placement.

    Device: Cochlear Nucleus CI632 cochlear implant

Interventions

  • ProcedureModified surgical approach

    An electrode typically placed under the temporalis muscle will be placed into the cochlear helicotrema instead.

  • DeviceCochlear Nucleus CI632 cochlear implant

    Cochlear implant (CI) system where stimulation from one of the intracochear electrodes is grounded via one of two (or both) extra cochlear electrodes in the device.

06

What researchers measure

Primary outcomes

  1. Upper Limit of Rate Pitch Perception for Cochlear Implant Stimuli

    The upper limit of rate pitch perception will be evaluated for Apex-monopolar (MP), 22-Apex, 22-MP, and 11-MP cochlear implant stimuli using a 3-up 1-down 2-interval forced-choice adaptive task. The task measures the highest modulation frequency perceived as a lower pitch compared to a rate 5 semitones higher. A series of 750-ms, 5000-pps pulse trains with 100% amplitude modulation will be presented at a loudness-balanced most-comfortable level. The upper limit will be estimated from the average modulation frequency of the last 6 reversals across 10 trials per stimulation site.

    Time frame: Month 12

  2. Mean pitch rank

    Pitch-ranking will be done using a 2-interval forced-choice protocol in which the pitch of a newly selected stimulus is ranked relative to the stimulus in the middle of a pitch-rank order list. Depending on the ranked pitch direction, this stimulus is repositioned in the pitch-rank order list and ranked against a neighboring stimulus until the correct position in the list is determined. This process repeated until all stimuli are successfully pitch ranked. A complete set of pitch ranks are measured 10 times allowing for the calculation of a mean rank and 95% confidence interval for the rank of each interval.

    Time frame: Month 12

  3. Percentage of Consonant-Nucleus-Consonant (CNC) words correctly repeated

    Speech perception will be assessed using CNC word lists, a common method for evaluating monosyllabic word recognition. The CNC Monosyllabic Word Test includes 10 lists of 50 words. The word test score range typically used is between 10% and 60% correct in the ear to be implanted, and equal to or better than that ear in the contralateral ear, but not better than 80% correct.

    Time frame: Month 12

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to:David.landsberger@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: Requests should be directed to David.landsberger@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Jan 2027, 53 months after the start.

Of 50 non-industry interventional studies with no phase under Deafness, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20. This study's planned 53 months is above that.

Counting every sponsor, half of 58 studies reached it within 31 months; a quarter within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Mar 30, 2025
StartActual
Aug 1, 2022
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06901674
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Mar 30, 2025
Start date
Aug 1, 2022
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Mar 6, 2026

Study contacts

David M. Landsberger, Ph.D.
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion